The deal, valued at €158 million, includes 13 established branded generic products with a presence across more than 55 countries spanning Europe, the Middle East and Africa.
The deal, valued at €158 million, includes 13 established branded generic products with a presence across more than 55 countries spanning Europe, the Middle East and Africa.